Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II exploratory study of dronedarone in metabolic-associated fatty liver disease
ChiCTR2500103656Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dronedarone in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Southwest Hospital of Army Medical University. Primary endpoints: Incidence of dose-limiting toxicity events and Optimal biological dose. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
dronedarone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2500103656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103656.